Blenrep (belantamab mafodotin) combinations approved in Japan for treatment of R/R multiple myeloma May 21, 2025
Next phase of clinical development for cemsidomide to be enabled with new studies expected to initiate in early 2026 May 13, 2025
Preliminary Clinical Data for CT0596 Announced, Demonstrating Favorable Safety and Efficacy May 13, 2025
Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of R/R Multiple Myeloma May 6, 2025
New long-term PFS data projections reinforce SC DARZALEX quadruplet therapy as a foundational SoC for patients with newly diagnosed multiple myeloma April 30, 2025
Blenrep (belantamab mafodotin) combinations approved by UK MHRA in R/R multiple myeloma April 22, 2025
BORUZU, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma, launched April 8, 2025
DARZALEX® (daratumumab) SC-based regimen receives positive CHMP opinion for patients with newly diagnosed multiple myeloma, regardless of transplant eligibility March 4, 2025
Linvoseltamab BLA Accepted for FDA Review for the Treatment of R/R Multiple Myeloma; PDUFA: 10Jul2025 February 19, 2025
Henlius and Dr. Reddy’s Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S. February 11, 2025
NMPA approves Sarclisa + SOC VRd in China for patients with newly diagnosed multiple myeloma ineligible for transplant February 4, 2025
Sarclisa + VRd combo approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant February 3, 2025
Sarclisa + VRd combo approved in the EU to treat transplant-ineligible newly diagnosed multiple myeloma January 23, 2025
Simnova and Orna Expand Strategic Partnership to Include BCMA-Targeted RNA Therapeutics January 21, 2025
Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma January 21, 2025
AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma January 15, 2025
New Sarclisa SC formulation met co-primary endpoints in the IRAKLIA Ph 3 study in multiple myeloma January 15, 2025
Sarclisa obtains NMPA approval in China for the treatment of adult patients with R/R multiple myeloma January 14, 2025
